Novartis, Molecular Partner team up on COVID-19 candidates


ZURICH, Oct 28 (Reuters) - Novartis NOVN.S has licenced global rights to two Molecular Partners MOLN.S antiviral drugs that have potential to treat COVID-19 patients, the two companies said on Wednesday.

Molecular Partners will get an upfront payment of 60 million Swiss francs ($66.2 million), a potential milestone payment of 150 million francs, and a "significant royalty" on sales of the drugs called MP0420 and MP0423.

($1 = 0.9070 Swiss francs)

(Reporting by John Miller)

((; +41 41 528 3630; Reuters Messaging:

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.